{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:03Z","timestamp":1792533603371,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["18-75-00050"],"award-info":[{"award-number":["18-75-00050"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the present work was to evaluate counts and functional properties of PD-1<jats:sup>+<\/jats:sup> and TIM-3<jats:sup>+<\/jats:sup> T cells in peripheral blood (PB) and bone marrow (BM) of multiple myeloma (MM) patients following the induction therapy. Sixty patients were enrolled in the study, CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells expressing PD-1 and TIM-3, intracellular production of IFN\u03b3 and intracellular expression of Granzyme B were assessed. Relative counts of the majority of circulating PD-1<jats:sup>+<\/jats:sup>, TIM-3<jats:sup>+<\/jats:sup> and PD-1<jats:sup>+<\/jats:sup>TIM-3<jats:sup>+<\/jats:sup> T cells were higher in MM patients with disease progression compared with individuals in remission. Frequencies of almost all evaluated PD-1<jats:sup>+<\/jats:sup> and TIM-3<jats:sup>+<\/jats:sup> T cell subsets were higher in BM samples compared with PB; circulating CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>TIM-3<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>TIM-3<jats:sup>+<\/jats:sup> T cells positively correlated with the same BM subsets. Circulating CD4<jats:sup>+<\/jats:sup> T cells, expressing PD-1 and TIM-3 (including co-expressing subset), as well as CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>TIM-3<jats:sup>+<\/jats:sup> T cells, and BM CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> T cells correlated with serum B2-M levels. Sufficient frequencies of GrB<jats:sup>+<\/jats:sup> and IFN\u03b3<jats:sup>+<\/jats:sup> subsets in PD-1-expressing T cells indicated their retained functional properties. TIM-3-expressing T cells and double positive PD-1<jats:sup>+<\/jats:sup>TIM-3<jats:sup>+<\/jats:sup> populations showed diminished cytotoxic and cytokine-producing ability and therefore might be attributed to the exhausted compartment. To identify T cell exhaustion, it is necessary to evaluate T cells co-expressing PD-1, TIM-3 and other inhibitory signal molecules and to study their functional properties. Sustained functionality of PD-1-positive T cells may explain low efficacy and frequent immune-mediated adverse events during anti-PD-1 therapy in MM.<\/jats:p>","DOI":"10.1038\/s41598-020-77941-y","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T11:03:35Z","timestamp":1606734215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Egor V.","family":"Batorov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana A.","family":"Aristova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera V.","family":"Sergeevicheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A.","family":"Sizikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina Y.","family":"Ushakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V.","family":"Pronkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Shishkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina Y.","family":"Shevela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Ostanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena R.","family":"Chernykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"77941_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"77941_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"77941_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"77941_CR4","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792\u2013e1792 (2015).","journal-title":"Cell Death Dis."},{"key":"77941_CR5","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G G\u00f6rg\u00fcn","year":"2015","unstructured":"G\u00f6rg\u00fcn, G. et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res. 21, 4607\u20134618 (2015).","journal-title":"Clin. Cancer Res."},{"key":"77941_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/sci.2017.03.04","volume":"4","author":"MJ Pianko","year":"2017","unstructured":"Pianko, M. J., Liu, Y., Bagchi, S. & Lesokhin, A. M. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig. 4, 32\u201332 (2017).","journal-title":"Stem Cell Investig."},{"key":"77941_CR7","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1111\/ajco.13033","volume":"14","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. Increased exhausted CD8 + T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma. Asia. Pac. J. Clin. Oncol. 14, e266\u2013e274 (2018).","journal-title":"Asia. Pac. J. Clin. Oncol."},{"key":"77941_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"77941_CR9","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen, R. et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J. Clin. Oncol. 35, 2125\u20132132 (2017).","journal-title":"J. Clin. Oncol."},{"key":"77941_CR10","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand, P. et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J. Clin. Oncol. 36, 1428\u20131439 (2018).","journal-title":"J. Clin. Oncol."},{"key":"77941_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2174\/1568009617666170906170348","volume":"17","author":"D Atanackovic","year":"2017","unstructured":"Atanackovic, D., Luetkens, T., Steinbach, M. & Kroger, N. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. Curr. Cancer Drug Targets 17, 839\u2013845 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"key":"77941_CR12","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin, A. M. et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J. Clin. Oncol. 34, 2698\u20132704 (2016).","journal-title":"J. Clin. Oncol."},{"key":"77941_CR13","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","volume":"29","author":"B Paiva","year":"2015","unstructured":"Paiva, B. et al. PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 29, 2110\u20132113 (2015).","journal-title":"Leukemia"},{"key":"77941_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc1704767","volume":"377","author":"C Melani","year":"2017","unstructured":"Melani, C. et al. PD-1 blockade in mediastinal gray-zone lymphoma. N. Engl. J. Med. 377, 89\u201391 (2017).","journal-title":"N. Engl. J. Med."},{"key":"77941_CR15","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MGM Roemer","year":"2016","unstructured":"Roemer, M. G. M. et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690\u20132697 (2016).","journal-title":"J. Clin. Oncol."},{"key":"77941_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02204","author":"F Costa","year":"2018","unstructured":"Costa, F., Das, R., Kini Bailur, J., Dhodapkar, K. & Dhodapkar, M. V. Checkpoint inhibition in myeloma: opportunities and challenges. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02204 (2018).","journal-title":"Front. Immunol."},{"key":"77941_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender, A., Addeo, A. & Banna, G. New emerging targets in cancer immunotherapy: The role of TIM3. ESMO Open https:\/\/doi.org\/10.1136\/esmoopen-2019-000497 (2019).","journal-title":"ESMO Open"},{"key":"77941_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil, F. M. et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J. Hematol. Oncol. 8, 93 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"77941_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fimmu.2016.00221","volume":"7","author":"NC Sabins","year":"2016","unstructured":"Sabins, N. C., Harman, B. C., Barone, L. R., Shen, S. & Santulli-Marotto, S. Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells. Front. Immunol. 7, 221 (2016).","journal-title":"Front. Immunol."},{"key":"77941_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.2013.098459","volume":"99","author":"FJ Gassner","year":"2014","unstructured":"Gassner, F. J. et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica 99, 67\u201369 (2014).","journal-title":"Haematologica"},{"key":"77941_CR21","doi-asserted-by":"publisher","first-page":"27305","DOI":"10.18632\/oncotarget.25553","volume":"9","author":"EV Batorov","year":"2018","unstructured":"Batorov, E. V. et al. Increased circulating CD4+FOXP3+ T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients. Oncotarget 9, 27305\u201327317 (2018).","journal-title":"Oncotarget"},{"key":"77941_CR22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178947","author":"S Danhof","year":"2018","unstructured":"Danhof, S. et al. Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Haematologica https:\/\/doi.org\/10.3324\/haematol.2017.178947 (2018).","journal-title":"Haematologica"},{"key":"77941_CR23","first-page":"304","volume":"11","author":"Y Chang","year":"2018","unstructured":"Chang, Y. et al. Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. Int. J. Clin. Exp. Pathol. 11, 304\u2013313 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"77941_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","volume":"63","author":"R Bataille","year":"1984","unstructured":"Bataille, R., Grenier, J. & Sany, J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment\u2014a prospective study of 160 patients. Blood 63, 468\u2013476 (1984).","journal-title":"Blood"},{"key":"77941_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/JCO.1984.2.1.51","volume":"2","author":"H Garewal","year":"1984","unstructured":"Garewal, H. et al. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J. Clin. Oncol. 2, 51\u201357 (1984).","journal-title":"J. Clin. Oncol."},{"key":"77941_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","volume":"75","author":"BG Durie","year":"1990","unstructured":"Durie, B. G. et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 75, 823\u2013830 (1990).","journal-title":"Blood"},{"key":"77941_CR27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"77941_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3346\/jkms.2013.28.4.542","volume":"28","author":"Y-U Cho","year":"2013","unstructured":"Cho, Y.-U. et al. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients. J. Korean Med. Sci. 28, 542\u2013549 (2013).","journal-title":"J. Korean Med. Sci."},{"key":"77941_CR29","doi-asserted-by":"publisher","first-page":"32024","DOI":"10.18632\/oncotarget.25882","volume":"9","author":"A-M Sponaas","year":"2018","unstructured":"Sponaas, A.-M. et al. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget 9, 32024\u201332035 (2018).","journal-title":"Oncotarget"},{"key":"77941_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2010.03255.x","author":"JS Yi","year":"2010","unstructured":"Yi, J. S., Cox, M. A. & Zajac, A. J. T-cell exhaustion: characteristics, causes and conversion. Immunology https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03255.x (2010).","journal-title":"Immunology"},{"key":"77941_CR31","doi-asserted-by":"publisher","first-page":"101042831769835","DOI":"10.1177\/1010428317698352","volume":"39","author":"Z Li","year":"2017","unstructured":"Li, Z., Liu, X., Guo, R. & Wang, P. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Tumor Biol. 39, 101042831769835 (2017).","journal-title":"Tumor Biol."},{"key":"77941_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775-789.e18 (2019).","journal-title":"Cell"},{"key":"77941_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"77941_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"77941_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","volume":"7","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J. Immunother. cancer 7, 331 (2019).","journal-title":"J. Immunother. cancer"},{"key":"77941_CR36","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77941-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:13:22Z","timestamp":1670372002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77941-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77941"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77941-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20846"}}